Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Robert Kozarski
Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet Oncology
Oncology
Use of Dynamic Contrast-Enhanced MR Imaging to Predict Survival in Patients With Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy
Radiology
Nuclear Medicine
Radiology
Imaging
Related publications
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology
A Phase 2 Trial of Abiraterone Acetate Without Glucocorticoids for Men With Metastatic Castration-Resistant Prostate Cancer
Cancer
Cancer Research
Oncology
A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
The Lancet Oncology
Oncology
Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients
Cancer Treatment and Research Communications
Cancer Research
Oncology
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet
Medicine
Phase 1 Trial of High-Dose Exogenous Testosterone in Patients With Castration-Resistant Metastatic Prostate Cancer
European Urology
Urology
Phase III, Randomized, Placebo-Controlled Study of Once-Daily Oral Zibotentan (ZD4054) in Patients With Non-Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer and Prostatic Diseases
Cancer Research
Oncology
Urology
